Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Theodore DeWeese

Theodore Leslie DeWeese, MD

Director, Department of Radiation Oncology and Molecular Radiation Sciences
Professor of Radiation Oncology and Molecular Radiation Sciences

See Research on Pubmed

Male
Appointment Phone

410-502-8000

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Director, Department of Radiation Oncology and Molecular Radiation Sciences
  • Radiation Oncologist -in-Chief
  • Professor of Radiation Oncology and Molecular Radiation Sciences
  • Professor of Oncology
  • Professor of Urology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Expertise

Cancer, Prostate Cancer, Radiation Oncology, Urological Oncology

Research Interests

Prostate Cancer; DNA damage; Radiation sensitization

Biography

Dr. Theodore DeWeese is a professor of radiation oncology and molecular radiation sciences, oncology and urology at the Johns Hopkins School of Medicine. His areas of clinical expertise include prostate cancer, radiation oncology and urological oncology.

He and his colleagues devised the first adenoviral gene therapy trial for prostate cancer, using a common cold virus to target cancer cells while leaving normal cells unharmed.

Dr. DeWeese serves as the director of the Department of Radiation Oncology and Molecular Radiation Sciences.

Dr. DeWeese received his B.A. from Metropolitan State College of Denver. He earned his M.D. from the University of Colorado Health Sciences Center. He completed his residency at The Johns Hopkins Hospital and performed a fellowship in urologic oncology at the Johns Hopkins Oncology Center and the James Buchanan Brady Urological Institute.

Previously at Johns Hopkins, Dr. DeWeese was an associate professor in oncology and urology and, later, the director of the radiation biology research program.

Dr. DeWeese''s research interests include prostate cancer, DNA damage and radiation sensitization.

Dr. DeWeese has served on committees for the American Association for Cancer Research and the American Society for Therapeutic Radiology and Oncology. He has received numerous awards and honors, including two teaching awards from the Johns Hopkins Oncology Center and an appointment as chief resident of radiation oncology at The Johns Hopkins Hospital in 1993-1994.

Languages

  • English

Memberships

American Association for Cancer Research, 1994

American College of Radiology, 1991

American Society for Therapeutic Radiology and Oncology, 1991

Clinical Trial Keywords

  • Prostate cancer
  • Gene therapy

Additional Resources

Additional Resources +
  • Education +

    Training

    • University of Colorado Health Sciences Center (Denver CO) (1990)

    Residencies

    • Johns Hopkins University School of Medicine / Radiation Oncology (Baltimore MD) (1994)

    Certifications

    • American Board of Radiology / Radiation Oncology (2005)
  • Research & Publications +

    Research Summary

    Dr. DeWeese has continued study of the role played by both Msh2 and GSTP1 in cellular oxidative damage tolerance. Previous studies performed by Dr. DeWeese’s laboratory have revealed that inactivation of alleles encoding the DNA mismatch repair enzyme, Msh2, result in enhanced survival following exposure to oxidative damage inflicted by protracted, low-dose ionizing radiation, accumulation of potentially mutagenic oxidized DNA bases and increased mutation frequency.

    Dr. DeWeese has expanded his study to other, more physiologically relevant oxidant stresses, including hypoxia. In this work, Dr. DeWeese has shown that exposure of mouse ES cells with inactivated Msh2 alleles to a hypoxia/reoxygenation event does not induce significant cell death, but it does induce a tenfold increase in the appearance of Hprt-mutant subclones. Moreover, Dr. DeWeese has identified a hotspot for hypoxia-induced mutations in the coding region of the murine Hprt gene. These data extend Dr. DeWeeses previous observations by revealing that Msh2 may be a general sensor of genomic DNA oxidant injury and that hypoxia can be a significant mutagenic stress in the face of altered DNA mismatch repair.

    Dr. DeWeese also continues to perform experiments with important clinical translation potential. These have included in vitro and in vivo experiments using human prostate cancer cells combining a replication-restricted, PSA-selective oncolytic adenoviral vector with radiation. These experiments reveal a real and significant mathematical synergy between this vector and radiation, with at least a sixfold increase in tumor control over that expected if the two therapies were simply additive. Other experiments performed by Dr. DeWeese and his collaborators revealed that one mechanism of this synergy includes radiation-induced enhancement of viral vectors. These data, combined with results from Dr. DeWeeses recently completed Phase I study, provide the rationale for clinical translation of a combination of this replication-restricted, PSA-selective oncolytic adenoviral vector and radiation to the clinic to treat men with newly diagnosed, clinically localized prostate cancer. In the search for other unique and clinically translatable methods of augmenting tumor radiation response, Dr. DeWeese is systematically studying a new method of disrupting cellular protein expression, using expression of unique, plasmid-based siRNA to silence genes that produce proteins involved in DNA double-strand break repair. As cellular radiation inflicts significant DNA double-strand breaks, modulation of double-strand break repair holds the promise of increased radiation-induced cell death. It is well known that cells and animals with inactivation of DNA-PKcs alleles or cells treated with inhibitors of DNA-PKcs exhibit enhanced radiation sensitization. Dr. DeWeese's lab has also developed siRNA targets to ATM and ATR, similarly important in the repair of genotoxic stress resulting from radiation and chemotherapy. This work is proceeding rapidly and has been expanded to include incorporation of these siRNA constructs into an adenoviral-based delivery system.

    Selected Publications View all on PubMed

    1. Kusano AS, Thomas CR Jr, Bonner JA, Deweese TL, Formenti SC, Hahn SM, Lawrence TS, Mittal BB. “Burnout in United States academic chairs of radiation oncology programs.” Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):363-8. doi: 10.1016/j.ijrobp.2013.09.027. Epub 2013 Nov 1.
    2. Wada S, Harris TJ, Tryggestad E, Yoshimura K, Zeng J, Yen HR, Getnet D, Grosso JF, Bruno TC, De Marzo AM, Netto GJ, Pardoll DM, DeWeese TL, Wong J, Drake CG. “Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.” Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):769-76.
    3. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G. “Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.” Mol Cancer Ther. 2013 Oct;12(10):2043-54. doi: 10.1158/1535-7163.MCT-13-0108. Epub 2013 Jul 19.
    4. Alcorn S, Walker AJ, Gandhi N, Narang A, Wild AT, Hales RK, Herman JM, Song DY, Deweese TL, Antonarakis ES, Tran PT. “Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.” Int J Mol Sci. 2013 Jul 16;14(7):14800-32.
    5. Narang AK, Lam E, Makary MA, Deweese TL, Pawlik TM, Pronovost PJ, Herman JM. “Accuracy of marketing claims by providers of stereotactic radiation therapy.”J Oncol Pract. 2013 Jan;9(1):57-62.
  • Academic Affiliations & Courses +
  • Activities & Honors +

    Honors

    Director’s Teaching Award in Clinical Science, The Johns Hopkins Oncology Center, 2003

    Director’s Teaching Award in Basic Science, The Johns Hopkins Oncology Center, 2002

    Doris Duke Research Scientist Award, 1999

    European Society for Therapeutic Radiology and Oncology Travel Award, 1998

    American Society for Therapeutic Radiology and Oncology Basic Science Travel Grant, 1995

    American Society for Therapeutic Radiology and Oncology Research Fellowship Award, 1994

    Chief Resident, Radiation Oncology, The Johns Hopkins Hospital, 1993-94

    Dean''s Letter of Academic Achievement, 1990

    Professional Activities

    Education Committee, American Association for Cancer Research, 2004

    Executive Committee, Cancer and Radiation Biology Committee, American Society for Therapeutic Radiology and Oncology, 2002

    Examiner, Genitourinary Section of Oral Boards for American Board of Radiology, 2002

  • Videos & Media +

    Videos

    Meet Our Expert: Dr. Theodore DeWeese

    Radiation oncologist Theodore DeWeese, the director of the Department of Radiation Oncology and Molecular Radiation Sciences, specializes in the treatment of patients with prostate cancer and other urological cancers. For more information, visit http://hopkinsmedicine.org/radiation_oncology

    C-Answers - Radiation Beams that Fight Cancer

    Dr. DeWeese explains the different types of radiation, how they are delivered and how they kill cancer cells.

    Advances in Prostate Cancer Radiation Therapy

    Video Links

    Recent News Articles & Media Coverage

  • Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-614-3979
    Appointment Phone: 410-502-8000
    Fax: 410-502-7234
    Location Map

    Department/Division

    • Radiation Oncology and Molecular Radiation Sciences

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer